{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:05:13Z","timestamp":1794632713913,"version":"4.9.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023A04J1785"],"award-info":[{"award-number":["2023A04J1785"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer is one of the most common malignant tumors worldwide, with metastasis being the leading cause of mortality among patients. Bone is the most frequent site of metastasis in breast cancer, accounting for approximately 70% of metastatic cases. Before bone metastasis, primary breast cancer cells secrete circulating factors (e.g., exosomal RNAs, metabolites, and cytokines) to precondition the bone microenvironment and establish a supportive pre-metastatic niche (PMN). After dissemination, tumor cells further hijack the bone niche by releasing receptor activator of nuclear factor-\u03baB ligand (RANKL), parathyroid hormone-related protein (PTHrP), and transforming growth factor-\u03b2 (TGF-\u03b2), thereby disrupting bone homeostasis through osteoclast activation and osteoblast dysregulation. Bone matrix degradation subsequently releases latent growth factors that in turn fuel tumor cell proliferation, thereby establishing a self-reinforcing vicious cycle. Meanwhile, breast cancer cells actively induce local immunosuppression and promote angiogenesis, remodeling a pro-tumor bone niche conducive to metastatic outgrowth. This review highlights the immunosuppressive roles of immune cells and key molecular mediators in the vicious cycle, systematically analyzes intercellular crosstalk within both the bone PMN and the hijacked niche, and summarizes emerging therapeutic strategies (including novel targeted inhibitors, immune-based combinations, epigenetic modulation, and nanomedicines) beyond conventional treatments. These insights provide a theoretical framework and identify promising therapeutic targets for future treatment strategies against breast cancer bone metastasis.<\/jats:p>","DOI":"10.1038\/s41413-026-00547-z","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:24:07Z","timestamp":1781083447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hijacking the bone niche: mechanistic insights into bone metastasis in breast cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Jiadi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-9923","authenticated-orcid":false,"given":"Yutian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"547_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X. et al. Breast cancer: pathogenesis and treatments. Signal Transduct. Target Ther. 10, 49 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"547_CR2","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477\u2013495 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"547_CR3","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271\u20133277 (2010).","journal-title":"J. Clin. Oncol."},{"key":"547_CR4","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid, M. et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108\u20133114 (2008).","journal-title":"Cancer Res."},{"key":"547_CR5","doi-asserted-by":"publisher","first-page":"a041326","DOI":"10.1101\/cshperspect.a041326","volume":"13","author":"E Nolan","year":"2023","unstructured":"Nolan, E., Kang, Y. & Malanchi, I. Mechanisms of organ-specific metastasis of breast cancer. Cold Spring Harb. Perspect. Med 13, a041326 (2023).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"547_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41422-023-00810-6","volume":"33","author":"Q Wu","year":"2023","unstructured":"Wu, Q. et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res. 33, 464\u2013478 (2023).","journal-title":"Cell Res."},{"key":"547_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/0008-5472.CAN-24-0479","volume":"85","author":"WJ Jiang","year":"2025","unstructured":"Jiang, W. J. et al. Breast cancer subtype-specific organotropism is dictated by FOXF2-regulated metastatic dormancy and recovery. Cancer Res. 85, 644\u2013659 (2025).","journal-title":"Cancer Res."},{"key":"547_CR8","first-page":"2464","volume":"10","author":"C Zhao","year":"2020","unstructured":"Zhao, C. et al. NAT1 promotes osteolytic metastasis in luminal breast cancer by regulating the bone metastatic niche via NF-kappaB\/IL-1B signaling pathway. Am. J. Cancer Res. 10, 2464\u20132479 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"547_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","volume":"18","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer, L. C. et al. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol. 18, 488\u2013505 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"547_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrc.2016.44","volume":"16","author":"PI Croucher","year":"2016","unstructured":"Croucher, P. I., Mcdonald, M. M. & Martin, T. J. Bone metastasis: the importance of the neighbourhood. Nat. Rev. Cancer 16, 373\u2013386 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"547_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1196\/annals.1365.035","volume":"1092","author":"DJ Hadjidakis","year":"2006","unstructured":"Hadjidakis, D. J. & Androulakis Ii. Bone remodeling. Ann. N. Y Acad. Sci. 1092, 385\u2013396 (2006).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"547_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2781","volume":"12","author":"YC Chen","year":"2010","unstructured":"Chen, Y. C., Sosnoski, D. M. & Mastro, A. M. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 12, 215 (2010).","journal-title":"Breast Cancer Res."},{"key":"547_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/bonekey.2013.215","volume":"3","author":"NA Sims","year":"2014","unstructured":"Sims, N. A. & Martin, T. J. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 3, 481 (2014).","journal-title":"Bonekey Rep."},{"key":"547_CR14","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti, J., Welm, A. L. & Stewart, S. A. Understanding the bone in cancer metastasis. J. Bone Min. Res. 33, 2099\u20132113 (2018).","journal-title":"J. Bone Min. Res."},{"key":"547_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1593","volume":"13","author":"M Zaidi","year":"2007","unstructured":"Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791\u2013801 (2007).","journal-title":"Nat. Med."},{"key":"547_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584\u2013593 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"547_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537\u2013549 (2003).","journal-title":"Cancer Cell"},{"key":"547_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature13145","volume":"507","author":"AP Kusumbe","year":"2014","unstructured":"Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature 507, 323\u2013328 (2014).","journal-title":"Nature"},{"key":"547_CR19","doi-asserted-by":"publisher","first-page":"10542","DOI":"10.1073\/pnas.1708161114","volume":"114","author":"F He","year":"2017","unstructured":"He, F. et al. Multiscale characterization of the mineral phase at skeletal sites of breast cancer metastasis. Proc. Natl. Acad. Sci. USA 114, 10542\u201310547 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"547_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.923371","volume":"10","author":"H Sun","year":"2022","unstructured":"Sun, H., Huang, W., Ji, F., Pan, Y. & Yang, L. Comparisons of metastatic patterns, survival outcomes and tumor immune microenvironment between young and non-young breast cancer patients. Front. Cell Dev. Biol. 10, 923371 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"547_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3922-0","volume":"18","author":"RK Hernandez","year":"2018","unstructured":"Hernandez, R. K. et al. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer 18, 44 (2018).","journal-title":"BMC Cancer"},{"key":"547_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/jcm2040264","volume":"2","author":"B Demirkan","year":"2013","unstructured":"Demirkan, B. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. J. Clin. Med. 2, 264\u2013282 (2013).","journal-title":"J. Clin. Med."},{"key":"547_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & Mccauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u2013425 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"547_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202504924","volume":"12","author":"J Ye","year":"2025","unstructured":"Ye, J. et al. Targeting hyperglycemic bone pre-metastatic niche for breast cancer bone metastasis therapy. Adv. Sci. 12, e04924 (2025).","journal-title":"Adv. Sci."},{"key":"547_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405257121","volume":"121","author":"I Baldassarri","year":"2024","unstructured":"Baldassarri, I. et al. An engineered model of metastatic colonization of human bone marrow reveals breast cancer cell remodeling of the hematopoietic niche. Proc. Natl. Acad. Sci. USA 121, e2405257121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"547_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41556-024-01478-9","volume":"26","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Lymphotoxin-beta promotes breast cancer bone metastasis colonization and osteolytic outgrowth. Nat. Cell Biol. 26, 1597\u20131612 (2024).","journal-title":"Nat. Cell Biol."},{"key":"547_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820\u2013827 (2005).","journal-title":"Nature"},{"key":"547_CR28","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1038\/s43018-024-00854-6","volume":"5","author":"KN Jackett","year":"2024","unstructured":"Jackett, K. N., Browne, A. T., Aber, E. R., Clements, M. & Kaplan, R. N. How the bone microenvironment shapes the pre-metastatic niche and metastasis. Nat. Cancer 5, 1800\u20131814 (2024).","journal-title":"Nat. Cancer"},{"key":"547_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329\u2013335 (2015).","journal-title":"Nature"},{"key":"547_CR30","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1111\/cas.14172","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang, L. et al. Bone sialoprotein-alphavbeta3 integrin axis promotes breast cancer metastasis to the bone. Cancer Sci. 110, 3157\u20133172 (2019).","journal-title":"Cancer Sci."},{"key":"547_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2021.05.016","volume":"22","author":"L Zhao","year":"2021","unstructured":"Zhao, L., Ma, X. & Yu, J. Exosomes and organ-specific metastasis. Mol. Ther. Methods Clin. Dev. 22, 133\u2013147 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"547_CR32","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.cmet.2021.09.002","volume":"33","author":"SM Morrissey","year":"2021","unstructured":"Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 33, 2040\u201358.e10 (2021).","journal-title":"Cell Metab."},{"key":"547_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2023.5287","volume":"52","author":"O Kim","year":"2023","unstructured":"Kim, O. et al. RAS\u2011stimulated release of exosomal miR\u2011494\u20113p promotes the osteolytic bone metastasis of breast cancer cells. Int. J. Mol. Med 52, 1\u201314 (2023).","journal-title":"Int. J. Mol. Med"},{"key":"547_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.7150\/thno.45351","volume":"11","author":"X Yuan","year":"2021","unstructured":"Yuan, X. et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics 11, 1429\u20131445 (2021).","journal-title":"Theranostics"},{"key":"547_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06156-4","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu, X. et al. Tumor-derived exosomal lncRNA-MIR193BHG promotes bone metastasis of breast cancer by targeting the miR-489-3p\/DNMT3A signaling axis in osteoclasts. J. Transl. Med. 23, 142 (2025).","journal-title":"J. Transl. Med."},{"key":"547_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cytogfr.2025.05.004","volume":"85","author":"W Luo","year":"2025","unstructured":"Luo, W. et al. TGF-beta-driven EMT in cancer progression and drug resistance. Cytokine Growth Factor Rev. 85, 11\u201325 (2025).","journal-title":"Cytokine Growth Factor Rev."},{"key":"547_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00018-023-05099-7","volume":"81","author":"W Xue","year":"2024","unstructured":"Xue, W. et al. Wnt\/beta-catenin-driven EMT regulation in human cancers. Cell Mol. Life Sci. 81, 79 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"547_CR38","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-10-2868","volume":"71","author":"HE Barker","year":"2011","unstructured":"Barker, H. E. et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res. 71, 1561\u20131572 (2011).","journal-title":"Cancer Res."},{"key":"547_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1158\/0008-5472.CAN-21-1012","volume":"82","author":"J Haj-Shomaly","year":"2022","unstructured":"Haj-Shomaly, J. et al. T cells promote metastasis by regulating extracellular matrix remodeling following chemotherapy. Cancer Res. 82, 278\u2013291 (2022).","journal-title":"Cancer Res."},{"key":"547_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06447-w","volume":"23","author":"G Khalili-Tanha","year":"2025","unstructured":"Khalili-Tanha, G., Radisky, E. S., Radisky, D. C. & Shoari, A. Matrix metalloproteinase-driven epithelial-mesenchymal transition: implications in health and disease. J. Transl. Med. 23, 436 (2025).","journal-title":"J. Transl. Med."},{"key":"547_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang, Y., Zhang, H., Song, X. & Yang, Q. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin. Cancer Biol. 60, 14\u201327 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"547_CR42","doi-asserted-by":"publisher","first-page":"9631","DOI":"10.1158\/0008-5472.CAN-10-0511","volume":"70","author":"CV Ustach","year":"2010","unstructured":"Ustach, C. V. et al. A novel signaling axis of matriptase\/PDGF-D\/ss-PDGFR in human prostate cancer. Cancer Res. 70, 9631\u20139640 (2010).","journal-title":"Cancer Res."},{"key":"547_CR43","doi-asserted-by":"publisher","first-page":"R788","DOI":"10.1186\/bcr1304","volume":"7","author":"I Carvalho","year":"2005","unstructured":"Carvalho, I., Milanezi, F., Martins, A., Reis, R. M. & Schmitt, F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 7, R788\u2013R795 (2005).","journal-title":"Breast Cancer Res."},{"key":"547_CR44","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1172\/JCI24652","volume":"116","author":"M Jechlinger","year":"2006","unstructured":"Jechlinger, M. et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. J. Clin. Investig. 116, 1561\u20131570 (2006).","journal-title":"J. Clin. Investig."},{"key":"547_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516\u2013523 (2006).","journal-title":"Curr. Opin. Cell Biol."},{"key":"547_CR46","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1023\/A:1023772912750","volume":"22","author":"JM Summy","year":"2003","unstructured":"Summy, J. M. & Gallick, G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22, 337\u2013358 (2003).","journal-title":"Cancer Metastasis Rev."},{"key":"547_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/35065016","volume":"410","author":"A Muller","year":"2001","unstructured":"Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50\u201356 (2001).","journal-title":"Nature"},{"key":"547_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10549-020-05596-4","volume":"181","author":"A Gennari","year":"2020","unstructured":"Gennari, A. et al. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Res. Treat. 181, 61\u201368 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"547_CR49","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41416-024-02852-y","volume":"131","author":"D Prasad","year":"2024","unstructured":"Prasad, D. et al. Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br. J. Cancer 131, 1543\u20131554 (2024).","journal-title":"Br. J. Cancer"},{"key":"547_CR50","doi-asserted-by":"publisher","first-page":"E992","DOI":"10.1073\/pnas.1718009115","volume":"115","author":"CS Devignes","year":"2018","unstructured":"Devignes, C. S. et al. HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc. Natl. Acad. Sci. USA 115, E992\u2013E1001 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"547_CR51","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-11-2904","volume":"18","author":"Q Chen","year":"2012","unstructured":"Chen, Q. & Massague, J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin. Cancer Res. 18, 5520\u20135525 (2012).","journal-title":"Clin. Cancer Res."},{"key":"547_CR52","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1541-7786.MCR-21-0243","volume":"19","author":"T Hiraga","year":"2021","unstructured":"Hiraga, T., Ito, S. & Mizoguchi, T. Opposing effects of granulocyte colony-stimulating factor on the initiation and progression of breast cancer bone metastases. Mol. Cancer Res. 19, 2110\u20132119 (2021).","journal-title":"Mol. Cancer Res."},{"key":"547_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1023\/A:1026526703898","volume":"1","author":"AC Karaplis","year":"2000","unstructured":"Karaplis, A. C. & Goltzman, D. PTH and PTHrP effects on the skeleton. Rev. Endocr. Metab. Disord. 1, 331\u2013341 (2000).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"547_CR54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315\u2013323 (1999).","journal-title":"Nature"},{"key":"547_CR55","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504\u20131508 (2000).","journal-title":"Science"},{"key":"547_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0484-9","volume":"16","author":"A Suvannasankha","year":"2014","unstructured":"Suvannasankha, A. & Chirgwin, J. M. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res. 16, 484 (2014).","journal-title":"Breast Cancer Res."},{"key":"547_CR57","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1016\/j.cell.2025.08.013","volume":"188","author":"Y Han","year":"2025","unstructured":"Han, Y. et al. Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. Cell 188, 6335\u201354.e26 (2025).","journal-title":"Cell"},{"key":"547_CR58","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/onc.2008.232","volume":"27","author":"Y Katsuno","year":"2008","unstructured":"Katsuno, Y. et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27, 6322\u20136333 (2008).","journal-title":"Oncogene"},{"key":"547_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2350-2","volume":"11","author":"W Si","year":"2020","unstructured":"Si, W., Zhou, J., Zhao, Y., Zheng, J. & Cui, L. SET7\/9 promotes multiple malignant processes in breast cancer development via RUNX2 activation and is negatively regulated by TRIM21. Cell Death Dis. 11, 151 (2020).","journal-title":"Cell Death Dis."},{"key":"547_CR60","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2016.06.007","volume":"380","author":"XQ Li","year":"2016","unstructured":"Li, X. Q., Lu, J. T., Tan, C. C., Wang, Q. S. & Feng, Y. M. RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization. Cancer Lett. 380, 78\u201386 (2016).","journal-title":"Cancer Lett."},{"key":"547_CR61","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","volume":"19","author":"N Sethi","year":"2011","unstructured":"Sethi, N., Dai, X., Winter, C. G. & Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192\u2013205 (2011).","journal-title":"Cancer Cell"},{"key":"547_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","volume":"27","author":"H Wang","year":"2015","unstructured":"Wang, H. et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193\u2013210 (2015).","journal-title":"Cancer Cell"},{"key":"547_CR63","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1016\/j.biomaterials.2011.03.055","volume":"32","author":"SP Pathi","year":"2011","unstructured":"Pathi, S. P., Lin, D. D., Dorvee, J. R., Estroff, L. A. & Fischbach, C. Hydroxyapatite nanoparticle-containing scaffolds for the study of breast cancer bone metastasis. Biomaterials 32, 5112\u20135122 (2011).","journal-title":"Biomaterials"},{"key":"547_CR64","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1111\/cas.15765","volume":"114","author":"T Hiraga","year":"2023","unstructured":"Hiraga, T., Horibe, K., Koide, M., Yamashita, T. & Kobayashi, Y. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells. Cancer Sci. 114, 2460\u20132470 (2023).","journal-title":"Cancer Sci."},{"key":"547_CR65","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/annonc\/mdn291","volume":"19","author":"RS Finn","year":"2008","unstructured":"Finn, R. S. Targeting Src in breast cancer. Ann. Oncol. 19, 1379\u20131386 (2008).","journal-title":"Ann. Oncol."},{"key":"547_CR66","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827\u2013839 (2003).","journal-title":"Circ. Res."},{"key":"547_CR67","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/0008-5472.CAN-15-2621","volume":"77","author":"C Reynaud","year":"2017","unstructured":"Reynaud, C. et al. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 77, 268\u2013278 (2017).","journal-title":"Cancer Res."},{"key":"547_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100522","volume":"44","author":"P Di Mauro","year":"2024","unstructured":"Di Mauro, P., Croset, M., Bouazza, L., Clezardin, P. & Reynaud, C. LOX, but not LOXL2, promotes bone metastasis formation and bone destruction in triple-negative breast cancer. J. Bone Oncol. 44, 100522 (2024).","journal-title":"J. Bone Oncol."},{"key":"547_CR69","doi-asserted-by":"publisher","first-page":"a031252","DOI":"10.1101\/cshperspect.a031252","volume":"8","author":"M Esposito","year":"2018","unstructured":"Esposito, M., Guise, T. & Kang, Y. The biology of bone metastasis. Cold Spring Harb. Perspect Med. 8, a031252 (2018).","journal-title":"Cold Spring Harb. Perspect Med."},{"key":"547_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fcell.2020.00076","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu, X. et al. RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front. Cell Dev. Biol. 8, 76 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"547_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1006\/bbrc.2001.5127","volume":"285","author":"S Corisdeo","year":"2001","unstructured":"Corisdeo, S., Gyda, M., Zaidi, M., Moonga, B. S. & Troen, B. R. New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem. Biophys. Res. Commun. 285, 335\u2013339 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"547_CR72","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fcell.2020.00433","volume":"8","author":"R Dai","year":"2020","unstructured":"Dai, R. et al. Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol. 8, 433 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"547_CR73","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1158\/1078-0432.CCR-04-2420","volume":"11","author":"M Chavez-Macgregor","year":"2005","unstructured":"Chavez-Macgregor, M. et al. Angiogenesis in the bone marrow of patients with breast cancer. Clin. Cancer Res. 11, 5396\u20135400 (2005).","journal-title":"Clin. Cancer Res."},{"key":"547_CR74","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224\u20131231 (2012).","journal-title":"Nat. Med."},{"key":"547_CR75","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ccell.2018.10.002","volume":"34","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. The osteogenic niche is a calcium reservoir of bone micrometastases and confers unexpected therapeutic vulnerability. Cancer Cell 34, 823\u201339.e7 (2018).","journal-title":"Cancer Cell"},{"key":"547_CR76","doi-asserted-by":"publisher","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","volume":"67","author":"C Le Gall","year":"2007","unstructured":"Le Gall, C. et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67, 9894\u20139902 (2007).","journal-title":"Cancer Res."},{"key":"547_CR77","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1158\/0008-5472.CAN-08-1078","volume":"68","author":"J Pratap","year":"2008","unstructured":"Pratap, J. et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 68, 7795\u20137802 (2008).","journal-title":"Cancer Res."},{"key":"547_CR78","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1158\/0008-5472.CAN-21-1331","volume":"82","author":"XQ Li","year":"2022","unstructured":"Li, X. Q., Zhang, R., Lu, H., Yue, X. M. & Huang, Y. F. Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells. Cancer Res. 82, 1560\u20131574 (2022).","journal-title":"Cancer Res."},{"key":"547_CR79","first-page":"95","volume":"146","author":"A Bellahcene","year":"1995","unstructured":"Bellahcene, A. & Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol. 146, 95\u2013100 (1995).","journal-title":"Am. J. Pathol."},{"key":"547_CR80","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/jbmr.5650110514","volume":"11","author":"A Bellahcene","year":"1996","unstructured":"Bellahcene, A., Kroll, M., Liebens, F. & Castronovo, V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Min. Res. 11, 665\u2013670 (1996).","journal-title":"J. Bone Min. Res."},{"key":"547_CR81","first-page":"179","volume":"26","author":"T Standal","year":"2004","unstructured":"Standal, T., Borset, M. & Sundan, A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp. Oncol. 26, 179\u2013184 (2004).","journal-title":"Exp. Oncol."},{"key":"547_CR82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin, J. J. et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig. 103, 197\u2013206 (1999).","journal-title":"J. Clin. Investig."},{"key":"547_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-024-02970-8","volume":"43","author":"K Yang","year":"2024","unstructured":"Yang, K. et al. IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis. J. Exp. Clin. Cancer Res. 43, 46 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"547_CR84","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41413-017-0006-3","volume":"6","author":"A Bartelt","year":"2018","unstructured":"Bartelt, A. et al. Lrp1 in osteoblasts controls osteoclast activity and protects against osteoporosis by limiting PDGF-RANKL signaling. Bone Res. 6, 4 (2018).","journal-title":"Bone Res."},{"key":"547_CR85","doi-asserted-by":"publisher","first-page":"R349","DOI":"10.1530\/ERC-17-0139","volume":"24","author":"C Zabkiewicz","year":"2017","unstructured":"Zabkiewicz, C., Resaul, J., Hargest, R., Jiang, W. G. & Ye, L. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocr. Relat. Cancer 24, R349\u2013R366 (2017).","journal-title":"Endocr. Relat. Cancer"},{"key":"547_CR86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jbmr.3869","volume":"35","author":"B Kim","year":"2020","unstructured":"Kim, B. et al. A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone. J. Bone Min. Res. 35, 155\u2013166 (2020).","journal-title":"J. Bone Min. Res."},{"key":"547_CR87","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2017.11.016","volume":"414","author":"C Lee","year":"2018","unstructured":"Lee, C. et al. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett. 414, 205\u2013213 (2018).","journal-title":"Cancer Lett."},{"key":"547_CR88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.joca.2008.09.007","volume":"17","author":"C Sanchez","year":"2009","unstructured":"Sanchez, C., Gabay, O., Salvat, C., Henrotin, Y. E. & Berenbaum, F. Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthr. Cartil. 17, 473\u2013481 (2009).","journal-title":"Osteoarthr. Cartil."},{"key":"547_CR89","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10456-020-09716-y","volume":"23","author":"QK Yang","year":"2020","unstructured":"Yang, Q. K., Chen, T., Wang, S. Q., Zhang, X. J. & Yao, Z. X. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself. Angiogenesis 23, 279\u2013298 (2020).","journal-title":"Angiogenesis"},{"key":"547_CR90","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1677\/joe.0.1700451","volume":"170","author":"GP Thomas","year":"2001","unstructured":"Thomas, G. P., Baker, S. U., Eisman, J. A. & Gardiner, E. M. Changing RANKL\/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170, 451\u2013460 (2001).","journal-title":"J. Endocrinol."},{"key":"547_CR91","first-page":"177","volume":"3","author":"K Tawara","year":"2011","unstructured":"Tawara, K., Oxford, J. T. & Jorcyk, C. L. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res. 3, 177\u2013189 (2011).","journal-title":"Cancer Manag. Res."},{"key":"547_CR92","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/jbmr.3133","volume":"32","author":"PL Mulcrone","year":"2017","unstructured":"Mulcrone, P. L. et al. Skeletal colonization by breast cancer cells is stimulated by an osteoblast and beta2AR-dependent neo-angiogenic switch. J. Bone Min. Res. 32, 1442\u20131454 (2017).","journal-title":"J. Bone Min. Res."},{"key":"547_CR93","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2353\/ajpath.2006.060180","volume":"169","author":"T Kawai","year":"2006","unstructured":"Kawai, T. et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol. 169, 987\u2013998 (2006).","journal-title":"Am. J. Pathol."},{"key":"547_CR94","doi-asserted-by":"publisher","first-page":"e010753","DOI":"10.1136\/jitc-2024-010753","volume":"13","author":"C Pilard","year":"2025","unstructured":"Pilard, C. et al. RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells. J. Immunother. Cancer 13, e010753 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"547_CR95","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1182\/blood-2002-09-2960","volume":"102","author":"M Choi","year":"2003","unstructured":"Choi, M. et al. Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. Blood 102, 2259\u20132267 (2003).","journal-title":"Blood"},{"key":"547_CR96","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673\u20132682 (2006).","journal-title":"J. Exp. Med."},{"key":"547_CR97","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1073\/pnas.0136772100","volume":"100","author":"G Toraldo","year":"2003","unstructured":"Toraldo, G., Roggia, C., Qian, W. P., Pacifici, R. & Weitzmann, M. N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA 100, 125\u2013130 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"547_CR98","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3390\/ijms25052688","volume":"25","author":"M Yang","year":"2024","unstructured":"Yang, M. & Zhu, L. Osteoimmunology: the crosstalk between T Cells, B Cells, and osteoclasts in rheumatoid arthritis. Int. J. Mol. Sci 25, 2688 (2024).","journal-title":"Int. J. Mol. Sci"},{"key":"547_CR99","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408, 600\u2013605 (2000).","journal-title":"Nature"},{"key":"547_CR100","doi-asserted-by":"publisher","first-page":"8287","DOI":"10.4049\/jimmunol.175.12.8287","volume":"175","author":"N Young","year":"2005","unstructured":"Young, N., Mikhalkevich, N., Yan, Y., Chen, D. & Zheng, W. P. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J. Immunol. 175, 8287\u20138295 (2005).","journal-title":"J. Immunol."},{"key":"547_CR101","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.3390\/cancers15113021","volume":"15","author":"R Wieder","year":"2023","unstructured":"Wieder, R. Awakening of dormant breast cancer cells in the bone marrow. Cancers 15, 3021 (2023).","journal-title":"Cancers"},{"key":"547_CR102","first-page":"e240294","volume":"32","author":"HQ Duong","year":"2025","unstructured":"Duong, H. Q., Kafer, G. & Maugham-Macan, M. Bone metastasis in endocrine-related cancer: unravelling invasion and destruction. Endocr. Relat. Cancer 32, e240294 (2025).","journal-title":"Endocr. Relat. Cancer"},{"key":"547_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116932","volume":"178","author":"AC Monteiro","year":"2024","unstructured":"Monteiro, A. C. et al. Cooperation between T and B cells reinforce the establishment of bone metastases in a mouse model of breast cancer. Bone 178, 116932 (2024).","journal-title":"Bone"},{"key":"547_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115755","volume":"143","author":"AC Monteiro","year":"2021","unstructured":"Monteiro, A. C. & Bonomo, A. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption. Bone 143, 115755 (2021).","journal-title":"Bone"},{"key":"547_CR105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41413-022-00237-6","volume":"11","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma. Bone Res. 11, 4 (2023).","journal-title":"Bone Res."},{"key":"547_CR106","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/jbmr.4615","volume":"37","author":"DL Arellano","year":"2022","unstructured":"Arellano, D. L. et al. Bone microenvironment-suppressed T cells increase osteoclast formation and osteolytic bone metastases in mice. J. Bone Min. Res. 37, 1446\u20131463 (2022).","journal-title":"J. Bone Min. Res."},{"key":"547_CR107","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ccell.2025.03.036","volume":"43","author":"JN Cheng","year":"2025","unstructured":"Cheng, J. N. et al. Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer Cell. 43, 1093\u2013107.e9 (2025).","journal-title":"Cancer Cell."},{"key":"547_CR108","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8970173","volume":"2021","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Immune checkpoint inhibitor therapy for bone metastases: specific microenvironment and current situation. J. Immunol. Res. 2021, 8970173 (2021).","journal-title":"J. Immunol. Res."},{"key":"547_CR109","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.3390\/ijms20225525","volume":"20","author":"K Maeda","year":"2019","unstructured":"Maeda, K. et al. The regulation of bone metabolism and disorders by Wnt signaling. Int. J. Mol. Sci. 20, 5525 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"547_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1429-0","volume":"10","author":"EK Breuer","year":"2019","unstructured":"Breuer, E. K. et al. Potassium channel activity controls breast cancer metastasis by affecting beta-catenin signaling. Cell Death Dis. 10, 180 (2019).","journal-title":"Cell Death Dis."},{"key":"547_CR111","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/jcm8020148","volume":"8","author":"PB Satriyo","year":"2019","unstructured":"Satriyo, P. B. et al. Cadherin 11 inhibition downregulates beta-catenin, deactivates the canonical WNT signalling pathway and suppresses the cancer stem cell-like phenotype of triple negative breast cancer. J. Clin. Med. 8, 148 (2019).","journal-title":"J. Clin. Med."},{"key":"547_CR112","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2014.07.010","volume":"353","author":"Y Xi","year":"2014","unstructured":"Xi, Y. & Chen, Y. Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett. 353, 8\u201316 (2014).","journal-title":"Cancer Lett."},{"key":"547_CR113","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1038\/sj.onc.1207892","volume":"23","author":"A Niida","year":"2004","unstructured":"Niida, A. et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin\/TCF pathway. Oncogene 23, 8520\u20138526 (2004).","journal-title":"Oncogene"},{"key":"547_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12807-0","volume":"10","author":"R Eyre","year":"2019","unstructured":"Eyre, R. et al. Microenvironmental IL1beta promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat. Commun. 10, 5016 (2019).","journal-title":"Nat. Commun."},{"key":"547_CR115","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.156","volume":"88","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel, P., D\u2019haese, P. & Brandenburg, V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 88, 235\u2013240 (2015).","journal-title":"Kidney Int."},{"key":"547_CR116","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ncb3613","volume":"19","author":"X Zhuang","year":"2017","unstructured":"Zhuang, X. et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat. Cell Biol. 19, 1274\u20131285 (2017).","journal-title":"Nat. Cell Biol."},{"key":"547_CR117","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bone.2009.06.010","volume":"45","author":"F Paic","year":"2009","unstructured":"Paic, F. et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone 45, 682\u2013692 (2009).","journal-title":"Bone"},{"key":"547_CR118","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/cells10061377","volume":"10","author":"K Venetis","year":"2021","unstructured":"Venetis, K. et al. Breast cancer with bone metastasis: molecular insights and clinical management. Cells 10, 1377 (2021).","journal-title":"Cells"},{"key":"547_CR119","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.7150\/jca.111680","volume":"16","author":"Q Bao","year":"2025","unstructured":"Bao, Q. et al. The dual roles of circular RNAs in breast cancer distant metastasis and their clinical applications. J. Cancer 16, 3270\u20133282 (2025).","journal-title":"J. Cancer"},{"key":"547_CR120","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/0008-5472.CAN-23-1899","volume":"84","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. CircMMP2(6,7) cooperates with beta-Catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis. Cancer Res. 84, 328\u2013343 (2024).","journal-title":"Cancer Res."},{"key":"547_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01394-8","volume":"20","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappaB\/bone remodeling factors signaling. Mol. Cancer 20, 98 (2021).","journal-title":"Mol. Cancer"},{"key":"547_CR122","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s12013-024-01332-7","volume":"82","author":"T Long","year":"2024","unstructured":"Long, T. & Tan, M. To investigate the role and potential mechanism of has_circ_RBMS3 in bone metastasis of breast cancer based on bioinformatics. Cell Biochem. Biophys. 82, 2227\u20132236 (2024).","journal-title":"Cell Biochem. Biophys."},{"key":"547_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.93","volume":"3","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. miRNA interplay: mechanisms and therapeutic interventions in cancer. MedComm\u2013Oncol. 3, e93 (2024).","journal-title":"MedComm\u2013Oncol."},{"key":"547_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100304","volume":"24","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. ceRNA network development and tumour-infiltrating immune cell analysis of metastatic breast cancer to bone. J. Bone Oncol. 24, 100304 (2020).","journal-title":"J. Bone Oncol."},{"key":"547_CR125","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2021.12.075","volume":"594","author":"Z Sun","year":"2022","unstructured":"Sun, Z. et al. LncRNA SNHG3 regulates the BMSC osteogenic differentiation in bone metastasis of breast cancer by modulating the miR-1273g-3p\/BMP3 axis. Biochem. Biophys. Res. Commun. 594, 117\u2013123 (2022).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"547_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154360","volume":"243","author":"J Zhu","year":"2023","unstructured":"Zhu, J. et al. LncRNA TRG-AS1 inhibits bone metastasis of breast cancer by the miR-877-5p\/WISP2 axis. Pathol. Res Pract. 243, 154360 (2023).","journal-title":"Pathol. Res Pract."},{"key":"547_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46602-3","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis. Nat. Commun. 15, 2384 (2024).","journal-title":"Nat. Commun."},{"key":"547_CR128","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.3390\/ijms22084072","volume":"22","author":"TS Barwal","year":"2021","unstructured":"Barwal, T. S. et al. MicroRNAs and long noncoding RNAs as novel therapeutic targets in estrogen receptor-positive breast and ovarian cancers. Int. J. Mol. Sci. 22, 4072 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"547_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou, Y. et al. Clinical approaches to overcome PARP inhibitor resistance. Mol. Cancer 24, 156 (2025).","journal-title":"Mol. Cancer"},{"key":"547_CR130","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1172\/JCI84424","volume":"127","author":"BD Adams","year":"2017","unstructured":"Adams, B. D., Parsons, C., Walker, L., Zhang, W. C. & Slack, F. J. Targeting noncoding RNAs in disease. J. Clin. Investig. 127, 761\u2013771 (2017).","journal-title":"J. Clin. Investig."},{"key":"547_CR131","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.2215","volume":"29","author":"M Croset","year":"2014","unstructured":"Croset, M. et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J. Bone Min. Res. 29, 1886\u20131899 (2014).","journal-title":"J. Bone Min. Res."},{"key":"547_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/srep40487","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu, J. et al. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Sci. Rep. 7, 40487 (2017).","journal-title":"Sci. Rep."},{"key":"547_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116683","volume":"231","author":"A Balkrishna","year":"2025","unstructured":"Balkrishna, A., Mittal, R., Bishayee, A., Kumar, A. P. & Bishayee, A. miRNA signatures affecting the survival outcome in distant metastasis of triple-negative breast cancer. Biochem. Pharm. 231, 116683 (2025).","journal-title":"Biochem. Pharm."},{"key":"547_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0746-0","volume":"17","author":"WL Cai","year":"2018","unstructured":"Cai, W. L. et al. microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11. Mol. Cancer 17, 9 (2018).","journal-title":"Mol. Cancer"},{"key":"547_CR135","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1158\/0008-5472.CAN-14-1026","volume":"75","author":"H Taipaleenmaki","year":"2015","unstructured":"Taipaleenmaki, H. et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 75, 1433\u20131444 (2015).","journal-title":"Cancer Res."},{"key":"547_CR136","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1158\/0008-5472.CAN-17-3058","volume":"78","author":"M Croset","year":"2018","unstructured":"Croset, M. et al. miRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. Cancer Res. 78, 5259\u20135273 (2018).","journal-title":"Cancer Res."},{"key":"547_CR137","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/0008-5472.CAN-15-2321","volume":"76","author":"BD Adams","year":"2016","unstructured":"Adams, B. D. et al. miR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer. Cancer Res. 76, 927\u2013939 (2016).","journal-title":"Cancer Res."},{"key":"547_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115139","volume":"130","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9. Bone 130, 115139 (2020).","journal-title":"Bone"},{"key":"547_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23156","volume":"36","author":"F Lv","year":"2022","unstructured":"Lv, F., Qin, J., Kong, S., Pan, L. & Ding, R. MicroRNA-506 ameliorates breast cancer-induced osteolytic bone metastasis via the NFATc-1 signaling pathway. J. Biochem. Mol. Toxicol. 36, e23156 (2022).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"547_CR140","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.7150\/ijbs.111356","volume":"21","author":"YY Law","year":"2025","unstructured":"Law, Y. Y. et al. Ugonin P mitigates osteolytic bone metastasis by suppressing MDK via upregulating miR-223-3p expression. Int. J. Biol. Sci. 21, 3740\u20133754 (2025).","journal-title":"Int. J. Biol. Sci."},{"key":"547_CR141","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature06174","volume":"449","author":"L Ma","year":"2007","unstructured":"Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682\u2013688 (2007).","journal-title":"Nature"},{"key":"547_CR142","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11914-021-00677-9","volume":"19","author":"M Puppo","year":"2021","unstructured":"Puppo, M., Valluru, M. K. & Clezardin, P. MicroRNAs and their roles in breast cancer bone metastasis. Curr. Osteoporos. Rep. 19, 256\u2013263 (2021).","journal-title":"Curr. Osteoporos. Rep."},{"key":"547_CR143","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/COC.0b013e3181deb9e5","volume":"33","author":"A Lipton","year":"2010","unstructured":"Lipton, A. Bone continuum of cancer. Am. J. Clin. Oncol. 33, S1\u2013S7 (2010).","journal-title":"Am. J. Clin. Oncol."},{"key":"547_CR144","doi-asserted-by":"publisher","first-page":"e250017","DOI":"10.6004\/jnccn.2025.0017","volume":"23","author":"JS Biermann","year":"2025","unstructured":"Biermann, J. S. et al. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J. Natl. Compr. Canc. Netw. 23, e250017 (2025).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"547_CR145","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"547_CR146","doi-asserted-by":"publisher","first-page":"337","DOI":"10.21147\/j.issn.1000-9604.2025.03.04","volume":"37","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study. Chin. J. Cancer Res. 37, 337\u2013351 (2025).","journal-title":"Chin. J. Cancer Res."},{"key":"547_CR147","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00198-024-07118-0","volume":"35","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi, T., Morimoto, T., Ito, K., Mawatari, M. & Shimazaki, T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos. Int. 35, 1377\u20131393 (2024).","journal-title":"Osteoporos. Int."},{"key":"547_CR148","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman, R. et al. Bone health in cancer: ESMO clinical practice guidelines. Ann. Oncol. 31, 1650\u20131663 (2020).","journal-title":"Ann. Oncol."},{"key":"547_CR149","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813\u2013822 (2011).","journal-title":"Lancet"},{"key":"547_CR150","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar, W. J. et al. Breast Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 22, 331\u2013357 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"547_CR151","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ctrv.2013.07.003","volume":"40","author":"M Gnant","year":"2014","unstructured":"Gnant, M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat. Rev. 40, 476\u2013484 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"547_CR152","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","volume":"94","author":"C Wilson","year":"2018","unstructured":"Wilson, C. et al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study. Eur. J. Cancer 94, 70\u201378 (2018).","journal-title":"Eur. J. Cancer"},{"key":"547_CR153","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman, R. et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 15, 997\u20131006 (2014).","journal-title":"Lancet Oncol."},{"key":"547_CR154","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1200\/JCO-24-02205","volume":"43","author":"L Mi","year":"2025","unstructured":"Mi, L. et al. Expanding the Horizon of MRONJ research in breast cancer bone metastasis treatments. J. Clin. Oncol. 43, 1168\u20131169 (2025).","journal-title":"J. Clin. Oncol."},{"key":"547_CR155","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/jbmr.4708","volume":"37","author":"G Yang","year":"2022","unstructured":"Yang, G. et al. Medication-related osteonecrosis of the jaw in cancer patients: result from the oneflorida clinical research consortium. J. Bone Min. Res. 37, 2466\u20132471 (2022).","journal-title":"J. Bone Min. Res."},{"key":"547_CR156","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.24.00171","volume":"43","author":"C Brunner","year":"2025","unstructured":"Brunner, C. et al. Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: a population-based multicenter retrospective study. J. Clin. Oncol. 43, 180\u2013188 (2025).","journal-title":"J. Clin. Oncol."},{"key":"547_CR157","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/biomedicines8040095","volume":"8","author":"G Tenore","year":"2020","unstructured":"Tenore, G. et al. Does medication-related osteonecrosis of the jaw influence the quality of life of cancer patients?. Biomedicines 8, 95 (2020).","journal-title":"Biomedicines"},{"key":"547_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110639","volume":"202","author":"M Kubeczko","year":"2025","unstructured":"Kubeczko, M. et al. Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4\/6 inhibitors. Radiother. Oncol. 202, 110639 (2025).","journal-title":"Radiother. Oncol."},{"key":"547_CR159","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.urology.2014.11.031","volume":"85","author":"ND Shore","year":"2015","unstructured":"Shore, N. D. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist\u2019s perspective. Urology 85, 717\u2013724 (2015).","journal-title":"Urology"},{"key":"547_CR160","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/DDDT.S122417","volume":"11","author":"E Deshayes","year":"2017","unstructured":"Deshayes, E. et al. Radium 223 dichloride for prostate cancer treatment. Drug Des. Devel Ther. 11, 2643\u20132651 (2017).","journal-title":"Drug Des. Devel Ther."},{"key":"547_CR161","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10549-023-07147-z","volume":"204","author":"HS Rugo","year":"2024","unstructured":"Rugo, H. S. et al. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials. Breast Cancer Res. Treat. 204, 249\u2013259 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"547_CR162","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.32604\/or.2024.046139","volume":"32","author":"A Wu","year":"2024","unstructured":"Wu, A. et al. Trametinib boosts palbociclib\u2019s efficacy in breast cancer via autophagy inhibition. Oncol. Res. 32, 1197\u20131207 (2024).","journal-title":"Oncol. Res."},{"key":"547_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217023","volume":"597","author":"AT Regua","year":"2024","unstructured":"Regua, A. T. et al. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers. Cancer Lett. 597, 217023 (2024).","journal-title":"Cancer Lett."},{"key":"547_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101126","volume":"77","author":"Y Zou","year":"2024","unstructured":"Zou, Y. et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist. Updat 77, 101126 (2024).","journal-title":"Drug Resist. Updat"},{"key":"547_CR165","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM Mcdonald","year":"2021","unstructured":"Mcdonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330\u201347.e13 (2021).","journal-title":"Cell"},{"key":"547_CR166","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00109-004-0612-6","volume":"83","author":"H Takayanagi","year":"2005","unstructured":"Takayanagi, H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83, 170\u2013179 (2005).","journal-title":"J. Mol. Med."},{"key":"547_CR167","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jare.2024.03.021","volume":"69","author":"J Zheng","year":"2025","unstructured":"Zheng, J. et al. Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction. J. Adv. Res. 69, 399\u2013411 (2025).","journal-title":"J. Adv. Res."},{"key":"547_CR168","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ccell.2017.11.002","volume":"32","author":"H Zheng","year":"2017","unstructured":"Zheng, H. et al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell 32, 731\u201347.e6 (2017).","journal-title":"Cancer Cell"},{"key":"547_CR169","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/1535-7163.MCT-14-0253","volume":"13","author":"LT Duong","year":"2014","unstructured":"Duong, L. T., Wesolowski, G. A., Leung, P., Oballa, R. & Pickarski, M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol. Cancer Ther. 13, 2898\u20132909 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"547_CR170","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-023-06873-8","volume":"199","author":"AJ Oswald","year":"2023","unstructured":"Oswald, A. J. et al. Aromatase inhibition plus\/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Res. Treat. 199, 35\u201346 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"547_CR171","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/s41418-019-0485-4","volume":"27","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell Death Differ. 27, 2066\u20132080 (2020).","journal-title":"Cell Death Differ."},{"key":"547_CR172","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.stem.2018.11.011","volume":"24","author":"PB Gupta","year":"2019","unstructured":"Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C. & Kuperwasser, C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 24, 65\u201378 (2019).","journal-title":"Cell Stem Cell"},{"key":"547_CR173","doi-asserted-by":"publisher","DOI":"10.34133\/research.0854","volume":"8","author":"J Zhang","year":"2025","unstructured":"Zhang, J. et al. PRMT1-mediated PARP1 methylation drives lung metastasis and chemoresistance via p65 activation in triple-negative breast cancer. Research 8, 0854 (2025).","journal-title":"Research"},{"key":"547_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217047","volume":"597","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation. Cancer Lett. 597, 217047 (2024).","journal-title":"Cancer Lett."},{"key":"547_CR175","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.devcel.2021.03.008","volume":"56","author":"IL Bado","year":"2021","unstructured":"Bado, I. L. et al. The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells. Dev. Cell 56, 1100\u20131117.e9 (2021).","journal-title":"Dev. Cell"},{"key":"547_CR176","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202402216","volume":"13","author":"D Fan","year":"2024","unstructured":"Fan, D. et al. Phosphate ion-responsive and calcium peroxide-based nanomedicine for bone-targeted treatment of breast cancer bone metastasis. Adv. Health. Mater. 13, e2402216 (2024).","journal-title":"Adv. Health. Mater."},{"key":"547_CR177","doi-asserted-by":"publisher","first-page":"769","DOI":"10.32604\/or.2023.044276","volume":"32","author":"H Gao","year":"2024","unstructured":"Gao, H. et al. Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases. Oncol. Res. 32, 769\u2013784 (2024).","journal-title":"Oncol. Res."},{"key":"547_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217260","volume":"604","author":"PT Winnard Jr","year":"2024","unstructured":"Winnard, P. T. Jr et al. Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment. Cancer Lett. 604, 217260 (2024).","journal-title":"Cancer Lett."},{"key":"547_CR179","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1515\/jtim-2024-0038","volume":"12","author":"Y Zou","year":"2024","unstructured":"Zou, Y., Zhang, H., Liu, F., Chen, Z. S. & Tang, H. Intratumoral microbiota in orchestrating cancer immunotherapy response. J. Transl. Int. Med 12, 540\u2013542 (2024).","journal-title":"J. Transl. Int. Med"},{"key":"547_CR180","doi-asserted-by":"publisher","first-page":"e144579","DOI":"10.1172\/JCI144579","volume":"132","author":"Z Yue","year":"2022","unstructured":"Yue, Z. et al. RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis. J. Clin. Investig. 132, e144579 (2022).","journal-title":"J. Clin. Investig."},{"key":"547_CR181","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/acscentsci.1c01024","volume":"8","author":"Z Tian","year":"2022","unstructured":"Tian, Z. et al. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone. ACS Cent. Sci. 8, 312\u2013321 (2022).","journal-title":"ACS Cent. Sci."},{"key":"547_CR182","volume":"7","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K. et al. Ononin inhibits tumor bone metastasis and osteoclastogenesis by targeting mitogen-activated protein kinase pathway in breast cancer. Resrarch 7, 0553 (2024).","journal-title":"Resrarch"}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00547-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00547-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00547-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:04:50Z","timestamp":1781089490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00547-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1038\/s41413-026-00547-z","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}